Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks

ATOSSA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.05

Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.
EVANGELINE study: 100% disease control rate, 37% avg lesion size reduction, 92% Ki-67 drop at 24 weeks.
Initiated combination study of (Z)-endoxifen + abemaciclib in ER+/HER2- breast cancer (20 patients).
I-SPY 2 Phase 2 trial fully enrolled; data readout expected in H2 2024.
Appointed medical oncologist Dr. Tessa Cigler to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.

Period: fiscal quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-058242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.